James Porter

James Porter

Auto-generated profile, based on publicly available information

James Porter

Swedish Medical Center, Seattle, WA 98122, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in European Urology
Verified
Journal Article
Closed access
BBBrian M. Benway
Brian M. Benway
SBSam B. Bhayani
Sam B. Bhayani
CRCraig G. Rogers
Craig G. Rogers
JPJames R. Porter
James R. Porter
NBNicolò M. Buffi
Nicolò M. Buffi
AMAlexandre M. Mottrie
Alexandre M. Mottrie

1 October 2016 in European Urology
Verified
Journal Article
Closed access
SSSevan Stepanian
Sevan Stepanian
MPMayank Patel
Mayank Patel
JPJames Porter
James Porter

31 March 2020 in BJU International
Verified
Journal Article
Closed access
PDF file
ABAaron W. Bradshaw
Aaron W. Bradshaw
RARiccardo Autorino
Riccardo Autorino
GSGiuseppe Simone
Giuseppe Simone
BYBo Yang
Bo Yang
RURobert G. Uzzo
Robert G. Uzzo
IDIthaar Derweesh
Ithaar Derweesh

1 August 2019 in European Urology
Verified
Journal Article
Closed access
PCPaolo Casale
Paolo Casale
GLGiovanni Lughezzani
Giovanni Lughezzani
NBNicolò Buffi
Nicolò Buffi
ALAlessandro Larcher
Alessandro Larcher
JPJames Porter
James Porter
AMAlex Mottrie
Alex Mottrie

1 August 2020 in BJU International
Verified
Journal Article
Closed access
PDF file
JPJames Porter
James Porter
EBElliot Blau
Elliot Blau
FGFarid Gharagozloo
Farid Gharagozloo
MMMartin Martino
Martin Martino
RCRobert Cerfolio
Robert Cerfolio
VPVipul Patel
Vipul Patel

13 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Aldo BrassettiAldo Brassetti
Aldo Brassetti
Giovanni E. CacciamaniGiovanni E. Cacciamani
Giovanni E. Cacciamani
Andrea MariAndrea Mari
Andrea Mari
JGJuan D. Garisto
Juan D. Garisto
Riccardo BertoloRiccardo Bertolo
Riccardo Bertolo
GSGiuseppe Simone
Giuseppe Simone
We compared perioperative outcomes after on-clamp versus off-clamp robot-assisted partial nephrectomy (RAPN) for >7 cm renal masses. A multicenter dataset was queried for patients who had undergone RAPN for a cT2cN0cM0 kidney tumor from July 2007 to February 2022. The Trifecta achievement (negative surgical margins, no severe complications, and ≤ 30% postoperative estimated glomerular filtration rate (eGFR) reduction) was considered a surrogate of surgical quality. Overall, 316 cases were included in the analysis, and 58% achieved the Trifecta. A propensity-score-matched analysis generated two cohorts of 89 patients homogeneous for age, ASA score, preoperative eGFR, and RENAL score (all p > 0.21). Compared to the on-clamp approach, OT was significantly shorter in the off-clamp group (80 vs. 190 min; p < 0.001), the incidence of sRFD was lower (22% vs. 40%; p = 0.01), and the Trifecta rate higher (66% vs. 46%; p = 0.01). In a crude analysis, >20 min of hilar clamping was associated with a significantly higher risk of sRFD (OR: 2.30; 95%CI: 1.13–4.64; p = 0.02) and with reduced probabilities of achieving the Trifecta (OR: 0.46; 95%CI: 0.27–0.79; p = 0.004). Purely off-clamp RAPN seems to be a safe and viable option to treat cT2 renal masses and may outperform the on-clamp approach regarding perioperative surgical outcomes.